 PDS Biotechnology Corp NASDAQ:PDSB shares are trading higher by 13.3 at 10.65 Tuesday morning after the company highlighted the release of interim data for PDS0101 in an NCI-led Phase 2 clinical study in oral presentation at the ASCO 2021 annual meeting. PDS Biotechnology Corp operates as a clinical-stage biotechnology company, principally involved in drug discovery in the United States. 